Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
β-Cyclodextrin-modified hyaluronic acid-based supramolecular self-assemblies for pH- and esterase- dual-responsive drug delivery.
Carbohydr Polym
October 2020
Shaanxi Key Laboratory of Polymer Science & Technology, OME Key Laboratory of Supernormal Material Physics & Chemistry, School of Chemistry and Chemical Engineering, Northwestern Polytechnical University, Xi'an, 710072, China. Electronic address:
Although some drug-based supramolecular systems have been constructed to overcome multidrug resistance and enhance the bioavailability of chemical drugs, strengthening the specific stimuli-responsive and active targeting ability of these systems is still a major challenge. In this paper, the synthesis and self-assembly behaviour of supramolecular self-assemblies with active targeting β-cyclodextrin-modified hyaluronic acid (HA-CD) and drug-drug conjugates (curcumin-oxoplatin, Cur-Pt) as building moieties were carefully investigated. Notably, the curcumin was chosen not only as the chemical anti-cancer drug, but also acted as the guest molecule which could be included into CD cavity to form host-guest interaction-based supramolecular assemblies.
View Article and Find Full Text PDFTheoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs.
Int J Mol Sci
July 2020
Reconocimiento y Encapsulación Molecular, Universidad Católica San Antonio de Murcia Campus los Jerónimos, 30107 Murcia, Spain.
Although Pt(II)-based drugs are widely used to treat cancer, very few molecules have been approved for routine use in chemotherapy due to their side-effects on healthy tissues. A new approach to reducing the toxicity of these drugs is generating a prodrug by increasing the oxidation state of the metallic center to Pt(IV), a less reactive form that is only activated once it enters a cell. We used theoretical tools to combine the parent Pt(IV) prodrug, oxoplatin, with the most recent FDA-approved anti-cancer drug set published by the National Institute of Health (NIH).
View Article and Find Full Text PDFHepatic arterial chemoembolization with CDDP microcapsules. Experimental studies.
Chin Med J (Engl)
February 1992
Institute of Hepatobiliary Surgery, Second Military Medical University, Shanghai.
After cis-diamminedichloroplatinum ethylcellulose microcapsules (CDDPmc) and unencapsulated CDDP were infused into the hepatic arteries of New Zealand rabbits, both CDDP concentrations in the circulating blood and in hepatic tissue were measured at different time intervals. In the rabbits infused with CDDPmc, the CDDP concentration was maintained at a high level for a significantly longer time in the hepatic tissue and the maximum CDDP level in the circulating blood was greatly reduced, as compared with those in the rabbits infused with unencapsulated CDDP. The tumoricidal effects of arterial infusion of CDDPmc were also evaluated in a model of liver tumor in rats.
View Article and Find Full Text PDFCross resistance studies with L1210 leukemia subline single and double resistant to cisplatin and iproplatin (CHIP).
Neoplasma
February 1991
Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Czechoslovakia.
Resistance to cisplatin (DDP) and/or iproplatin (CHIP) was induced in vitro in murine L1210 leukemia cells. Double-resistant sublines with combined resistance to both drugs were also developed. Cross resistance investigations with DDP, CHIP, oxoplatinum (OXO), carboplatin (CBDCA) and its quadrivalent derivative OXOCBDCA were performed in these resistant sublines.
View Article and Find Full Text PDFThe time-course of plasma and red blood cells platinum concentration was investigated after the administration of cis-dichlorodiammineplatinum II (cisplatinum), cis-dichlorodiammine-trans-dihydroxyplatinum IV (oxoplatinum), cis-dichloro-trans-dihydroxy-bis-isopropylamine-platinum IV (CHIP) and cis-diammine-1,1-cyclobutanedicarboxylate-platinum II (CBDCA) to male Wistar rats. A physiologically based three-compartment open model was used for pharmacokinetic evaluation. This model provides an estimation of free and protein-bound platinum time-courses from the total platinum species decrease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!